We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Abbott to Market Mad Cow Tests for Cattle

By Labmedica staff writers
Posted on 29 Mar 2001
Abbott Laboratories (Abbott Park, IL, USA) has entered into an agreement with Enfer Scientific Ltd. More...
(Tipperary, Ireland) for the marketing and distribution of two diagnostic tests developed by Enfer to detect bovine encephalopathy (BSE), or mad cow disease, in cattle. Abbott will market the tests under the Enfer name.

The tests detect the presence of the abnormal prion protein associated with BSE. One test is a four-hour enzyme-linked immunosorbent assay (ELISA), approved by the European Commission. The test's rapid turnaround time and high throughput capabilities make it well suited for testing for mad cow disease. The second test is a supplemental diagnostic test used to confirm positive results of the first test. Both tests are conducted on brain tissue and spinal cord samples from cattle.

"We believe we have two very effective tests that improve the speed and reliability of BSE testing,” said Louis Ronan, director of Enfer Scientific. "By helping to ensure that only BSE-free meat enters the human food chain, these tests are making an important contribution to public safety.”




Related Links:
Abbott Diagnostics

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.